Why is Fredun Pharma falling/rising?

As of 24-Sep, Fredun Pharmaceuticals Ltd is experiencing a price increase, currently at 1,255.00, reflecting a rise of 26.4 or 2.15%. The stock has shown a positive performance today, outperforming its sector by 2.6%, and has gained consecutively over the last two days, with a total return of 3.14% during this period. The stock reached an intraday high of Rs 1277.95, indicating strong investor interest. Additionally, Fredun Pharma has demonstrated impressive long-term growth, with net sales increasing at an annual rate of 38.16% and operating profit at 56.18%. The company has reported positive results for the last five consecutive quarters, contributing to its favorable valuation and market-beating performance, as it generated a return of 62.02% over the past year while the broader market has declined. In the broader market context, while the stock has shown resilience and growth, the benchmark index, Sensex, has declined by 1.18% over the past week and has generated negative returns of -3.77% over the last year. This contrast highlights Fredun Pharmaceuticals' strong performance relative to the market. Despite the positive indicators, it is worth noting that domestic mutual funds hold no stake in the company, which may reflect some underlying caution regarding its valuation or business prospects. Overall, the stock's recent rise can be attributed to its strong financial performance and positive investor sentiment, even as the broader market faces challenges.